Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
GSK just fired Moncef Slaoui from his post as Galvani Bioelectronics board chairman this week. The executive also served as the chief scientist for the U.S. government’s Operation Warp Speed, a coronavirus vaccine development group under Donald Trump’s administration.
CNBC reported that GlaxoSmithKline terminated Slaoui due to sexual harassment claims that were raised by a woman who was not named. His dismissal was announced by GSK on March 24.
The alleged offenses that led to Slaoui’s dismissal
Slaoui was a scientist and board chair at Galvani Bioelectronics, where GSK is a major shareholder. This is why it was GlaxoSmithKline that made the decision to get rid of him.
Moreover, it was revealed that in February, GSK received a letter that described Slaoui’s sexual harassment offenses and other misconducts committed toward the company’s employees. Based on the allegations, Dr. Slaoui’s inappropriate conduct happened several years ago when he was still working directly for GlaxoSmithKline.
After the concerns have been raised over the former board chairman’s behavior, GSK acted swiftly and axed the erring executive. His dismissal is effective immediately. At any rate, Slaoui lost his job 10 months after Trump appointed him to manage the country’s effort to develop COVID-19 vaccines.
“Dr. Slaoui's behaviors are wholly unacceptable,” GSK stated via a press release that was posted on March 24. “They represent an abuse of his leadership position, violate company policies, and are contrary to the strong values that define GSK's culture.”
It was added that everyone at GSK is expected to behave in accordance with the company’s values, especially its leaders. The firm then stressed that sexual harassment and other abuse of leadership are not tolerated and strictly prohibited.
About Moncef Slaoui
The fired Moncef Slaoui is 61 years old now and has been with GSK for 30 years. His wife, Kristen Slaoui, was a former GSK’s vice president and head of business development in the past.
When he was assigned as the chief advisor of Operation Warp Speed, he was a board member at Moderna pharmaceuticals. Due to criticisms for his connection to Moderna, while being an official at OWS, he resigned from the board of Moderna and sold his shares. However, Slaoui refused to give up his shares in GSK and said that those are his “retirement plan.”
